Embed Size (px)
DESCRIPTION
Astellas prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16
Citation preview
© Datamonitor
the home of Business Intelligence
intuitive deliveryexpert analysisquality data
© Datamonitor
PharmaVitae: Astellas Pharma Inc.HC00068-027Slidepack09/11
quality data expert analysis intuitive deliverythe home of Business Intelligence
Astellas prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16
-2,000
0
2,000
4,000
6,000
8,000
10,000
12,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
-10%
0%
10%
20%
30%
40%
50%
60%
Yea
r-on
-yea
r gro
wth
rate
(%)
Growth rate Sales ($m)
Astellas financial performance ($m), 2004–16
-15,000
-10,000
-5,000
0
5,000
10,000
15,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Rx pharma Other revenues COGS
S,G&A R&D Other operating expense
Operating profit
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Astellas Eli Lilly GlaxoSmithKline Pfizer Bayer Rest of market
Urology product sales by company ($m), 2004–16
Astellas prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16
-2,000
0
2,000
4,000
6,000
8,000
10,000
12,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
-10%
0%
10%
20%
30%
40%
50%
60%
Yea
r-on
-yea
r gro
wth
rate
(%)
Growth rate Sales ($m)
Astellas’s key product sales ($m), 2004–16
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
Rest of portfolio Vesicare Micardis Prograf Tarceva Celecox Advagraf Lipitor Harnal Gaster
Astellas’s key product growth drivers and resistors ($m), 2004–10
0
2,000
4,000
6,000
8,000
10,000
12,000
2004
Pro
graf
Ves
icar
e
Mic
ardi
s
Ser
oque
l
Cel
ecox
Tarc
eva
Gas
ter
Har
nal
Res
t of
portf
olio
2010
Sal
es ($
m)
Start / end year Positive growth Negative growth
Astellas’s key product growth drivers and resistors ($m), 2010–16
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
2010
Ves
icar
e
Bet
anis
Cel
ecox
Adv
agra
f
Vib
ativ
Har
nal
Pro
graf
Res
t of
portf
olio
2016
Sal
es ($
m)
Start / end year Positive growth Negative growth
Astellas prescription pharmaceutical sales by therapy area ($m), 2004–16
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
CV Uro I&I ID Onco CNS GE Resp Hema Musco Endo
Astellas prescription pharmaceutical sales by geographic region ($m), 2004–16
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
Japan US RoW 5EU
Astellas launch, core and expiry configuration, sales ($m), 2010–16
11,43010,867
+1,094+1,642
-77-2,096
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
2010
Laun
ch
Cor
e
Exp
iry
Gen
eric
2016
Sal
es ($
m)
Start / end year Positive growth Negative growth
Astellas prescription pharmaceutical sales by molecule type ($m), 2004–16
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
Small molecule Therapeutic protein Vaccine
Astellas prescription pharmaceutical sales by source of product ($m), 2004–16
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
Internal In-licensed M&A Co-developed Acquired product
Astellas Group operating revenue/cost analysis ($m), 2004–16
-15,000
-10,000
-5,000
0
5,000
10,000
15,000
04 05 06 07 08 09 10 11 12 13 14 15 16
Rx pharma Other revenues COGS
S,G&A R&D Other operating expense
Operating profit
Vesicare sales by geography and analyst consensus ($m), 2004–16
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
US 5EU JAPAN ROW Analyst consensus Global
Micardis sales by geography and analyst consensus ($m), 2004–16
0
200
400
600
800
1,000
1,200
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
US 5EU JAPAN ROW Analyst consensus Global
Prograf sales by geography and analyst consensus ($m), 2004–16
0
500
1,000
1,500
2,000
2,500
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
US 5EU JAPAN ROW Analyst consensus Global
Celecox sales by geography and analyst consensus ($m), 2004–16
0
100
200
300
400
500
600
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
US 5EU JAPAN ROW Analyst consensus Global
Tarceva sales by geography and analyst consensus ($m), 2004–16
0
100
200
300
400
500
600
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
US 5EU JAPAN ROW Analyst consensus Global
Lipitor sales by geography and analyst consensus ($m), 2004–16
0
200
400
600
800
1,000
1,200
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
US 5EU JAPAN ROW Analyst consensus Global
Betanis sales by geography and analyst consensus ($m), 2004–16
0
50
100
150
200
250
300
350
400
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
US 5EU JAPAN ROW Analyst consensus Global
Harnal sales by geography and analyst consensus ($m), 2004–16
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
04 05 06 07 08 09 10 11 12 13 14 15 16
Sal
es ($
m)
US 5EU JAPAN ROW Analyst consensus Global
© Datamonitor
the home of Business Intelligence
intuitive deliveryexpert analysisquality data
© Datamonitor
